Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
humanized CD19 CAR-T cells with TLR2
- Development stage
- Phase 1
- Lead developer
- Southern Medical University Zhujiang Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Humanized CD19 CAR-T cells with TLR2 is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Zhujiang Hospital. The therapy consists of T cells genetically engineered to express a humanized CAR targeting the CD19 antigen, which is expressed on the surface of B-cell lineage cells. Uniquely, this CAR construct incorporates a Toll-like receptor 2 (TLR2) signaling domain alongside standard T-cell activation components. The inclusion of the TLR2 domain is intended to enhance the expansion, persistence, and cytotoxic activity of the CAR-T cells by providing potent costimulatory signals. It is currently being investigated in a Phase 1 clinical trial for the treatment of adult patients with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) or B-cell lymphoblastic lymphoma (B-LBL) who are ineligible for or intolerant to intensive chemotherapy regimens.
- Other names
- humanized CD19-TLR2 CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on humanized CD19 CAR-T cells with TLR2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on humanized CD19 CAR-T cells with TLR2.